CRG-023
-
CRG-023, A Novel Tri-Specific CAR T Product Candidate Engineered to Prevent Antigen Escape and Sustain Durable Anti-Tumor Functionality Against B-Cell Malignancies
ASH 2024
-
CD22-Targeted CAR T Cell Single Cell Multiomic Features Linked To Patient Outcomes In CD19-CAR Resistant Large B Cell Lymphoma
Kramer et al, EHA 2024
-
CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering
Majzner et al, Nature Medicine 2019
